Source comparison
MOTS-c Fat Loss Results Timeline Expect: Comparison by Protocol
First Detectable Metabolic Change Day 10–14 Day 18–25 (lower bioavailability) Injection formats produce faster AMPK activation due to direct systemic delivery Measurable Fat Loss Onset Week 4–5 Week 6–8 Oral formats require higher dosing and show delayed onset
This comparison does not assign a generated winner or score.
- First Detectable Metabolic Change
- Day 10–14
- Day 18–25 (lower bioavailability)
- Injection formats produce faster AMPK activation due to direct systemic delivery
- Measurable Fat Loss Onset
- Week 4–5
- Week 6–8
- Oral formats require higher dosing and show delayed onset due to first-pass metabolism
- Peak Metabolic Effect Window
- Week 8–10
- Week 10–14
- All formats plateau at similar timeframes when dosed appropriately
- Lean Mass Preservation vs Deficit Alone
- +2–4% vs baseline
- +1–2% vs baseline
- Subcutaneous administration consistently shows superior muscle retention during energy restriction
- Insulin Sensitivity Improvement (HOMA-IR reduction)
- 15–25% by week 6
- 10–18% by week 8
- Injectable MOTS-c produces faster and more pronounced insulin sensitivity gains
- The table above reflects observational data from research protocols and user logs. Not FDA-approved clinical endpoints. MOTS-c is not an approved pharmaceutical for fat loss or metabolic disease. Its use in humans remains investigational.